ARS Investment Partners’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $7.08M | Sell |
28,118
-30
| -0.1% | -$6.45K | 0.31% | 54 |
|
|
2026
Q1 | $6.12M | Sell |
28,148
-145
| -0.5% | -$32.2K | 0.32% | 51 |
|
|
2025
Q4 | $6.46M | Sell |
28,293
-183
| -0.6% | -$41.7K | 0.38% | 48 |
|
|
2025
Q3 | $6.59M | Sell |
28,476
-913
| -3% | -$186K | 0.44% | 44 |
|
|
2025
Q2 | $5.46M | Buy |
29,389
+383
| +1% | +$71.2K | 0.4% | 45 |
|
|
2025
Q1 | $5.15M | Hold |
29,006
| – | – | 0.47% | 44 |
|
|
2024
Q4 | $5.15M | Sell |
29,006
-850
| -3% | -$156K | 0.46% | 44 |
|
|
2024
Q3 | $5.9M | Buy |
29,856
+180
| +0.6% | +$33.6K | 0.53% | 42 |
|
|
2024
Q2 | $5.09M | Sell |
29,676
-1,002
| -3% | -$166K | 0.49% | 44 |
|
|
2024
Q1 | $5.59M | Hold |
30,678
| – | – | 0.56% | 42 |
|
|
2023
Q4 | $4.75M | Sell |
30,678
-45
| -0.1% | -$6.56K | 0.53% | 41 |
|
|
2023
Q3 | $4.58M | Sell |
30,723
-90
| -0.3% | -$13.2K | 0.57% | 41 |
|
|
2023
Q2 | $4.15M | Buy |
30,813
+1,572
| +5% | +$231K | 0.49% | 43 |
|
|
2023
Q1 | $4.66M | Buy |
29,241
+350
| +1% | +$53.5K | 0.56% | 45 |
|
|
2022
Q4 | $4.67M | Sell |
28,891
-10,090
| -26% | -$1.55M | 0.62% | 43 |
|
|
2022
Q3 | $5.23M | Buy |
38,981
+6,840
| +21% | +$982K | 0.72% | 39 |
|
|
2022
Q2 | $4.92M | Hold |
32,141
| – | – | 0.67% | 41 |
|
|
2022
Q1 | $5.21M | Sell |
32,141
-971
| -3% | -$141K | 0.5% | 44 |
|
|
2021
Q4 | $4.48M | Sell |
33,112
-1,053
| -3% | -$124K | 0.41% | 52 |
|
|
2021
Q3 | $3.69M | Sell |
34,165
-60,927
| -64% | -$6.96M | 0.37% | 53 |
|
|
2021
Q2 | $10.7M | Buy |
95,092
+1,228
| +1% | +$138K | 1.09% | 31 |
|
|
2021
Q1 | $10.2M | Buy |
93,864
+348
| +0.4% | +$37.2K | 1.18% | 28 |
|
|
2020
Q4 | $10M | Buy |
93,516
+12,876
| +16% | +$1.24M | 1.23% | 27 |
|
|
2020
Q3 | $7.06M | Buy |
80,640
+113
| +0.1% | +$10.6K | 1.11% | 28 |
|
|
2020
Q2 | $7.91M | Buy |
80,527
+74,647
| +1,270% | +$6.57M | 1.49% | 23 |
|
|
2020
Q1 | $448K | Hold |
5,880
| – | – | 0.11% | 66 |
|
|
2019
Q4 | $521K | Buy |
5,880
+3,200
| +119% | +$266K | 0.09% | 84 |
|
|
2019
Q3 | $203K | Sell |
2,680
-3,000
| -53% | -$206K | 0.04% | 104 |
|
|
2019
Q2 | $413K | Buy |
5,680
+800
| +16% | +$62.9K | 0.07% | 105 |
|
|
2019
Q1 | $393K | Sell |
4,880
-18,319
| -79% | -$1.5M | 0.07% | 93 |
|
|
2018
Q4 | $2.14M | Sell |
23,199
-215,267
| -90% | -$18.9M | 0.45% | 46 |
|
|
2018
Q3 | $22.6M | Sell |
238,466
-16,863
| -7% | -$1.6M | 3.49% | 7 |
|
|
2018
Q2 | $23.7M | Buy |
255,329
+930
| +0.4% | +$90.8K | 3.77% | 4 |
|
|
2018
Q1 | $24.1M | Buy |
254,399
+81,101
| +47% | +$8.91M | 2.95% | 8 |
|
|
2017
Q4 | $16.8M | Buy |
173,298
+367
| +0.2% | +$34.6K | 2.03% | 16 |
|
|
2017
Q3 | $15.4M | Buy |
172,931
+3,127
| +2% | +$238K | 1.98% | 17 |
|
|
2017
Q2 | $12.3M | Buy |
169,804
+19,367
| +13% | +$1.3M | 1.7% | 22 |
|
|
2017
Q1 | $9.8M | Buy |
+150,437
| New | +$9.46M | 1.42% | 24 |
|
|
2016
Q3 | – | Sell |
-54,555
| Closed | -$3.38M | – | 87 |
|
|
2016
Q2 | $3.38M | Sell |
54,555
-4,114
| -7% | -$251K | 0.76% | 48 |
|
|
2016
Q1 | $3.35M | Sell |
58,669
-4,959
| -8% | -$276K | 0.79% | 45 |
|
|
2015
Q4 | $3.77M | Sell |
63,628
-121,203
| -66% | -$6.98M | 0.89% | 41 |
|
|
2015
Q3 | $10.1M | Sell |
184,831
-25,355
| -12% | -$1.65M | 2.3% | 12 |
|
|
2015
Q2 | $14.1M | Sell |
210,186
-1,499
| -0.7% | -$97.9K | 2.58% | 11 |
|
|
2015
Q1 | $12.4M | Buy |
211,685
+32,327
| +18% | +$1.95M | 2.3% | 15 |
|
|
2014
Q4 | $11.7M | Buy |
179,358
+57,124
| +47% | +$3.6M | 2% | 20 |
|
|
2014
Q3 | $7.06M | Buy |
122,234
+185
| +0.2% | +$10.3K | 1.08% | 36 |
|
|
2014
Q2 | $6.89M | Sell |
122,049
-4,430
| -4% | -$232K | 1.07% | 33 |
|
|
2014
Q1 | $6.5M | Sell |
126,479
-8,004
| -6% | -$405K | 1.15% | 32 |
|
|
2013
Q4 | $7.1M | Sell |
134,483
-11,665
| -8% | -$573K | 1.19% | 29 |
|
|
2013
Q3 | $6.54M | Sell |
146,148
-8,277
| -5% | -$367K | 1.11% | 35 |
|
|
2013
Q2 | $6.38M | Buy |
+154,425
| New | +$6.75M | 1.12% | 33 |
|
Other funds holding ABBV
ARS Investment Partners's ABBV Position: Q2 2026 in Review
ARS Investment Partners reduced its AbbVie (ABBV) stake by 0.11% in Q2 2026, selling an estimated $6.45K and leaving 28,118 shares worth $7.08M. The position accounts for 0.31% of the portfolio, ranked #54.
ARS Investment Partners first reported a position in ABBV in Q2 2013 and has held it in 51 quarters since. The position peaked at $24.1M in Q1 2018. 4,193 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- ARS Investment Partners held 28,118 shares of AbbVie worth $7.08M as of Q2 2026.
- ARS Investment Partners sold 30 AbbVie shares in Q2 2026, an estimated $6.45K.
- AbbVie made up 0.31% of ARS Investment Partners's portfolio in Q2 2026, its #54 holding.
- ARS Investment Partners first reported a position in AbbVie in Q2 2013 and has held it in 51 quarters since.
- ARS Investment Partners's AbbVie position peaked at $24.1M in Q1 2018.
- 4,193 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on ARS Investment Partners's 13F filing for Q2 2026, filed 9 Jul 2026.